Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice

Aim: The aim of this study was to evaluate the efficacy and safety of the new ultra-long-acting insulin degludec (Tresiba®) in the treatment of type 2 diabetes in routine clinical practice.Methods: This primary health care clinical observational study included 20 insulin-naïve type 2 diabetic patien...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lyudmila Alexandrovna Suplotova, Nikolay Valer'evich Plotnikov, Natal'ya Valer'yanovna Romanova, Larisa Nikolaevna Bel’chikova, Ekaterina Viktorovna Khieva, Marina Vladimirovna Shestakova
Formato: article
Lenguaje:EN
RU
Publicado: Endocrinology Research Centre 2015
Materias:
Acceso en línea:https://doaj.org/article/bb9f11fa3266492f955d458c1ee4ebc2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!